Cargando…
Hyaluronan signaling and turnover /
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers hyaluronan signaling and turnover. Provides information on cancer research...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
San Diego, California :
Elsevier,
2014.
|
| Edición: | First edition. |
| Colección: | Advances in cancer research ;
v. 123. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn889271702 | ||
| 003 | OCoLC | ||
| 005 | 20231120111717.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 140805t20142014cauaf ob 001 0 eng d | ||
| 040 | |a E7B |b eng |e rda |e pn |c E7B |d OCLCO |d UIU |d N$T |d YDXCP |d OCLCF |d OCLCQ |d EBLCP |d OHS |d DEBSZ |d CASUM |d OCLCQ |d OCLCO |d OCLCA |d FEM |d OCLCQ |d OCLCO |d OCLCA |d MERUC |d OCLCO |d MEU |d OCLCQ |d D6H |d OCLCO |d CNCGM |d OCLCO |d UPM |d OCLCO |d OCLCQ |d OTZ |d OCLCQ |d OCLCO |d OCLCA |d VT2 |d OCLCO |d OCLCQ |d OCL |d OCLCO | ||
| 019 | |a 885123479 |a 960214102 |a 968117026 |a 968993773 |a 1027704072 | ||
| 020 | |a 9780128003930 |q (electronic bk.) | ||
| 020 | |a 0128003936 |q (electronic bk.) | ||
| 020 | |z 9780128000922 | ||
| 020 | |z 0128000929 | ||
| 035 | |a (OCoLC)889271702 |z (OCoLC)885123479 |z (OCoLC)960214102 |z (OCoLC)968117026 |z (OCoLC)968993773 |z (OCoLC)1027704072 | ||
| 050 | 4 | |a RC270.8 |b .H935 eb | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.99406 |2 23 |
| 245 | 0 | 0 | |a Hyaluronan signaling and turnover / |c edited by Melanie A. Simpson, Paraskevi Heldin. |
| 250 | |a First edition. | ||
| 264 | 1 | |a San Diego, California : |b Elsevier, |c 2014. | |
| 264 | 4 | |c �2014 | |
| 300 | |a 1 online resource (418 pages, 26 unnumbered pages of plates) : |b color illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Online resource; title from PDF title page (ebrary, viewed August 5, 2014). | |
| 505 | 0 | |a Front Cover; Hyaluronan Signaling and Turnover; Copyright; Contents; Contributors; Preface; Chapter One: Emerging Roles for Hyaluronidase in Cancer Metastasis and Therapy; 1. Introduction; 2. Of Mole Rats and Men: Insights About HA and Cancer; 2.1. HA and hyaluronidase accelerate human cancers; 2.2. Naked mole rats resist cancer; 3. Hyaluronidase Expression in Cancer; 3.1. Hyal1; 3.2. Hyal2; 3.3. Hyal3, Hyal4, and PH-20; 4. Hyaluronidase Function and the Metastatic Process; 4.1. Vesicle trafficking and cell motility; 4.2. Vesicle shedding. | |
| 505 | 8 | |a 4.3. Products of hyaluronidase: Fragments versus oligos4.4. Products of hyaluronidase: Beyond HA; 5. Hyaluronidase Targeting in Cancer Therapy and Imaging; 5.1. Structural and functional features of human Hyals; 5.2. Targeting of hyaluronidase for cancer therapy; 5.3. Hyaluronidase-targeting agents for tumor imaging; 6. Conclusions and Future Perspective; Acknowledgments; References; Chapter Two: Targeting Hyaluronic Acid Family for Cancer Chemoprevention and Therapy; 1. Introduction; 2. Targeting HA Production; 2.1. Targeting HA synthases; 2.2. Chemical inhibitors of HA synthesis. | |
| 505 | 8 | |a 2.2.1. 4-Methylumbelliferone2.2.2. Other HA synthesis inhibitors; 3. Targeting HA Signaling; 3.1. HA oligosaccharides; 4. HA as a Carrier for Drug Delivery; 5. Targeting HA Receptors; 5.1. CD44; 5.1.1. CD44 vaccines; 5.1.2. CD44 siRNA delivery; 5.1.3. Targeting CD44 for delivering antitumor therapies; 5.1.4. Targeting of CD44 protein; 5.2. RHAMM; 6. Targeting HAase; 7. Conclusion; Acknowledgments; References; Chapter Three: Aberrant Posttranscriptional Processing of Hyaluronan Synthase 1 in Malignant Transformation and Tumor Prog ... ; 1. Splicing and Cancer; 1.1. Splicing in the human genome. | |
| 505 | 8 | |a 2. Control of Pre-mRNA Splicing2.1. Splicing mutations; 3. Impact on Cancer of Alterations in Splicing Machinery; 4. Aberrant Splicing of Hyaluronan Synthase 1; 4.1. B lineage malignancies; 4.1.1. Multiple myeloma; 4.1.2. Waldenstrom macroglobulinemia; 4.2. Aberrant splice variants in hyaluronan synthase 1; 5. Clinical Impact of Aberrant HAS1 Splicing; 6. Genetic Variations in HAS1; 7. Functional Impact of HAS1Vs; 7.1. Synthesis of HA; 7.2. Functional outcomes of HA synthesis in patients; 7.2.1. Motility and malignant spread; 7.2.2. HAS1Vs and oncogenic events. | |
| 505 | 8 | |a 7.2.3. Intermolecular interactions of HAS1Vs7.2.4. HAS1Vs and genetic instability; 8. Functional Outcomes of HAS1Vs in Transfectants; 8.1. HAS1Vs synthesize intracellular HA; 8.2. HAS1FL and HAS1Vs form heteromultimers with HAS1Vs as the dominant partners; 8.3. Multimers with HAS1Vs stabilize HAS1FL and maintain intracellular HA; 9. HAS1Vs and Mitotic Catastrophe; 9.1. A potential mechanism underlying the oncogenic properties of aberrant HAS1 splice variants: HAS1V-mediated rescue fro ... ; 9.1.1. Receptor for hyaluronan-mediated motility (RHAMM). | |
| 520 | |a Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers hyaluronan signaling and turnover. Provides information on cancer research Outstanding and original reviews Suitable for researchers and students. | ||
| 546 | |a Text in English. | ||
| 650 | 0 | |a Cancer |x Treatment. | |
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Oncology. | |
| 650 | 0 | |a Cellular signal transduction. | |
| 650 | 1 | 2 | |a Hyaluronic Acid |x physiology |0 (DNLM)D006820Q000502 |
| 650 | 1 | 2 | |a Neoplasms |0 (DNLM)D009369 |
| 650 | 2 | 2 | |a Medical Oncology |0 (DNLM)D008495 |
| 650 | 2 | 2 | |a Signal Transduction |0 (DNLM)D015398 |
| 650 | 6 | |a Cancer |x Traitement. |0 (CaQQLa)201-0004693 | |
| 650 | 6 | |a Cancer. |0 (CaQQLa)201-0004683 | |
| 650 | 6 | |a Canc�erologie. |0 (CaQQLa)201-0014055 | |
| 650 | 6 | |a Transduction du signal cellulaire. |0 (CaQQLa)201-0206812 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Oncology |2 fast |0 (OCoLC)fst01045739 | |
| 650 | 7 | |a Cellular signal transduction |2 fast |0 (OCoLC)fst00850288 | |
| 650 | 7 | |a Cancer |2 fast |0 (OCoLC)fst00845317 | |
| 650 | 7 | |a Cancer |x Treatment |2 fast |0 (OCoLC)fst00845538 | |
| 655 | 4 | |a Internet Resources. | |
| 655 | 4 | |a Plates. | |
| 700 | 1 | |a Simpson, Melanie A., |e editor. | |
| 700 | 1 | |a Heldin, Paraskevi, |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Hyaluronan signaling and turnover. |b First edition. |d San Diego, California : Elsevier, �2014 |h xvi, 385 pages |k Advances In Cancer Research ; Volume 123 |x 0065-230X |z 9780128000922 |
| 830 | 0 | |a Advances in cancer research ; |v v. 123. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128000922 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/0065230X/123 |z Texto completo |